Quanterix

Quanterix FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Quanterix (QTRX) as of Nov 3, 2026 is 74.52 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 100.00 % — a change of -25.48% (lower).

FCF Conversion

74.52 %

YoY

-25.48%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Quanterix is 2025 74.52 % . FCF Conversion Rate (FCF/EBITDA) of Quanterix was 2024 100.00 % . It decreases by -25.48% lower compared to the previous year.

The Quanterix FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
97.40 USD
Jan 1, 2019
90.78 USD
Jan 1, 2020
86.57 USD
Jan 1, 2021
106.65 USD
Jan 1, 2022
60.25 USD
Jan 1, 2023
80.02 USD
Jan 1, 2024
100.00 USD
Jan 1, 2025
74.52 USD
The Quanterix FCF Conversion history
YEARFCF ConversionYoY
74.52 %-25.48%
100.00 %+24.97%
80.02 %+32.81%
60.25 %-43.50%
106.65 %+23.19%
86.57 %-4.64%
90.78 %-6.80%
97.40 %+13.25%
86.01 %+9.10%
78.83 %-4.16%
82.26 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quanterix Stock analysis

What does Quanterix do? Quanterix Corp is a company specialized in the development and distribution of innovative instruments and technologies for the precise measurement of biomarkers. The company was founded in 2007 by a renowned expert team in biotechnology and diagnostics and is headquartered in Lexington, Massachusetts, USA. The history of Quanterix Corp began with the vision of finding new ways to diagnose diseases earlier and more accurately. The founders recognized that conventional diagnostic methods are often inaccurate and time-consuming, and saw great potential in improving diagnostics through the targeted measurement of specific biomarkers. They wanted to establish a company specialized in the development of technologies for this type of diagnostics. Today, Quanterix Corp is a leading provider of ultrasensitive tests and technologies for biomarker measurement. The company has various divisions, including Life Sciences and Diagnostics. In the field of Life Sciences, Quanterix offers instruments and kits for biomarker research and development. They utilize the patented Simoa technology (Single Molecule Array), which enables ultrasensitive biomarker measurement in conjunction with digital detection systems. In the field of Diagnostics, Quanterix offers ultrasensitive tests for various clinical applications. Here, the company works closely with industry partners and academic institutions to utilize the technology in clinical research and diagnostics. The goal is to optimize therapy decisions, monitor treatment outcomes, and identify early indications of diseases. Quanterix products are in demand worldwide and are used in various fields. For example, tests for neurodegenerative diseases such as Alzheimer's, Parkinson's, or ALS are offered. These tests can help track disease progression and improve diagnosis. Quanterix's ultrasensitive tests also play a role in oncology, where they can help detect cancer early or measure treatment success. Quanterix's business model is based on collaboration with partners from the pharmaceutical industry, academic institutions, and clinics. Quanterix sees itself as an enabler for the development of new therapies and diagnostic methods. Through collaboration with various partners, new innovations in research and diagnostics are made possible. In summary, Quanterix Corp is a leading company in the development and marketing of ultrasensitive tests and technologies for biomarker measurement. The company has various divisions and offers products for Life Sciences as well as Diagnostics. The Simoa technology allows for higher precision and accuracy in biomarker measurement. Quanterix's goal is to promote medical progress and provide patients with better diagnostic and therapeutic care through its technologies and tests. Quanterix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Quanterix stock

FCF Conversion Rate (FCF/EBITDA) of Quanterix is 74.52 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Quanterix changed from 100.00 % to 74.52 %, representing a -25.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Quanterix since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Quanterix with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Quanterix

All Key Metrics — Quanterix